Specifically, the findings demonstrate that serum LIF levels are associated with TKI-targeted therapy, while serum TGF-β1 and cTnT levels are related to preclinical cardiovascular injuries in NSCLC patients. This evidence concerns the gene LIF and non-small cell lung carcinoma.